Brainjo Secures €2m in Seed Funding for VR Mental Health Tech

Key Takeaways

• brainjo raised €2 million (~$2.2 million) seed round.
• Funding led by High‑Tech Gründerfonds, includes MEDICE strategic partner.
• First VR DiGA targets children with ADHD, market launch slated 2028.
• VR tool prescribed by clinicians, reimbursed through German DiGA system.
• Aims to reduce therapy waitlists and improve patient adherence.

Pulse Analysis

Virtual reality is transitioning from a novelty to a clinically validated modality in mental‑health care. In Europe, the DiGA framework allows digital therapeutics to be prescribed by physicians and reimbursed by statutory health insurance, creating a clear pathway for innovators. This regulatory environment encourages startups to invest heavily in evidence generation, as approval hinges on rigorous clinical data and cost‑effectiveness analyses.

brainjo’s seed financing, anchored by High‑Tech Gründerfonds and bolstered by MEDICE and HTGF, underscores investor confidence in VR‑driven DiGAs. The company’s inaugural product tackles ADHD in children—a segment where traditional therapy often faces long wait times and limited access. By integrating immersive VR experiences that can be used at home, brainjo aims to improve adherence and provide clinicians with a scalable adjunct to conventional treatment. The €2 million capital will fund a pivotal clinical trial and support the regulatory dossier needed for German market entry by 2028.

If successful, brainjo could set a precedent for multimodal therapy models that blend in‑person care with digital extensions. Such solutions promise to alleviate pressure on overburdened mental‑health services while delivering measurable outcomes to payers. The broader industry is watching, as the convergence of VR technology, digital health reimbursement, and venture capital could accelerate the adoption of similar prescribable tools across Europe and eventually the United States.